Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day - Slideshow

Akebia Therapeutics hosted an R&D Day in April 2026 to outline progress in its kidney disease treatment pipeline, emphasizing strategic priorities and clinical advancements. The company highlighted vadadustat, its lead hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for anemia in chronic kidney disease (CKD), with updated trial data and regulatory plans. Development updates included AK-1179, a novel oral therapy for CKD-related hyperphosphatemia, with Phase 2 results expected soon, reinforcing its focus on unmet needs in nephrology. Strategic partnerships and commercialization efforts were discussed, aiming to expand market reach for approved therapies while advancing late-stage candidates. Investor presentations underscored financial stability, pipeline milestones, and long-term growth potential in kidney disease therapeutics.